{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:05:14Z","timestamp":1785456314786,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtct.2025.12.987","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:07:18Z","timestamp":1766131638000},"page":"446.e1-446.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding Hodgkin and B-Cell Non-Hodgkin Lymphoma Progression in Patients Awaiting Autologous Transplant in a Resource-Constrained Setting"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7212-530X","authenticated-orcid":false,"given":"Rodrigo Br\u00eatas Emerich","family":"Nogueira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6096-116X","authenticated-orcid":false,"given":"Joaquim Gasparini dos","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Jun","family":"Otuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina Arrais","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Junqueira","family":"Atanazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Maria","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Dolphini","family":"Velasques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9228-3276","authenticated-orcid":false,"given":"Lu\u00eds Alberto de P\u00e1dua Covas","family":"Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Buccheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Fatobene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jtct.2025.12.987_bib0001","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.987_bib0002","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.12.987_bib0003","unstructured":"Rocha, V., Hendricks, C.L., Narula, G., Ahme, S.O., & Koh, M.B.C. (2025). Overcoming socioeconomic and other barriers to CAR-T therapy access across healthcare systems (Chap. 61). In M. Aljurf, C. Bonini, C. Chabannon (Ed-in-Chief), J. Delgado, M. Dreyling, J. Kuball, A. Ruggeri, M. Subklewe, & A. Sureda (Eds.), The EU CAR-T Handbook. Available at:https:\/\/creativecommons.org\/licenses\/by\/4.0\/. (Accessed August 16, 2025)."},{"issue":"3","key":"10.1016\/j.jtct.2025.12.987_bib0004","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.htct.2023.03.021","article-title":"Impact of waitlist time on post-HSCT survival: a cohort study at a hospital in southern Brazil","volume":"46","author":"Silva","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"issue":"27","key":"10.1016\/j.jtct.2025.12.987_bib0005","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.987_bib0006","first-page":"1","article-title":"Outcomes of refractory and relapsed hodgkin lymphoma with autologous stem-cell transplantation: a single institution experience","author":"Wali","year":"2019","journal-title":"J Glob Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.987_bib0007","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.987_bib0008","doi-asserted-by":"crossref","first-page":"1001.e1","DOI":"10.1016\/j.jtct.2024.07.008","article-title":"Autologous stem cell transplant in fit patients with late relapsed diffuse large b-cell lymphoma that responded to salvage chemotherapy","volume":"30","author":"Tun","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.987_bib0009","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.2023023525","article-title":"Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study","volume":"144","author":"Malinverni","year":"2024","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2025.12.987_bib0010","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.987_bib0011","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00277-023-05511-z","article-title":"Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care","volume":"103","author":"Bostankolu De\u011firmenci","year":"2024","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.987_bib0012","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1016\/j.clml.2022.04.020","article-title":"Multiple myeloma: impact of time to transplant on the outcome","volume":"22","author":"Kumar","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.987_bib0013","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/hematology.2021000258","article-title":"Increasing access to allogeneic hematopoietic cell transplant: an international perspective","volume":"2021","author":"Rocha","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.987_bib0014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.46765\/2675-374X.2023v4n3p217","article-title":"Barriers to access of hematopoietic stem cell transplantation: an integrative review","volume":"4","author":"Feliciano","year":"2023","journal-title":"J Bone Marrow Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.987_bib0015","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/S2666-6367(22)00245-7","article-title":"84 - Evaluation of disease progression\/relapse in patients with multiple myeloma waiting for autologous hematopoietic cell transplant from a resource-constrained country","volume":"28","author":"Fatobene","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"10.1016\/j.jtct.2025.12.987_bib0016","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V128.22.690.690","article-title":"Impact of wait times for autologous stem cell transplantation in patients with aggressive non-hodgkin lymphoma, a subset analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial","volume":"128","author":"Skamene","year":"2016","journal-title":"Blood"},{"issue":"8852","key":"10.1016\/j.jtct.2025.12.987_bib0017","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"9323","key":"10.1016\/j.jtct.2025.12.987_bib0018","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.987_bib0019","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41409-025-02568-4","volume":"60","author":"Mart\u00ednez","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2025.12.987_bib0020","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1182\/bloodadvances.2023011205","article-title":"Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era","volume":"7","author":"Desai","year":"2023","journal-title":"Blood Adv [Internet]"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.987_bib0021","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41375-022-01563-8","article-title":"The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years","volume":"36","author":"Bazarbachi","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.987_bib0022","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ajh.23897","article-title":"The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"90","author":"Kako","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.987_bib0023","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.987_bib0024","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/bmt.2015.177","article-title":"A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma","volume":"50","author":"Satwani","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.987_bib0025","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed hodgkin\u2019s lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.987_bib0026","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hon.2604","article-title":"Reassessment of risk factors and long-term results of autologous stem cell transplantation in relapsed and refractory classical Hodgkin lymphoma","volume":"37","author":"Fatobene","year":"2019","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.987_bib0027","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.987_bib0028","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.jtct.2025.12.987_bib0029","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1182\/bloodadvances.2024013743","article-title":"Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation","volume":"8","author":"Epperla","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.987_bib0030","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/hon.2796","article-title":"Rescue of chemorefractory classical Hodgkin lymphoma with nivolumab and autologous stem-cell transplantation: real-life experience","volume":"39","author":"Buccheri","year":"2021","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.987_bib0031","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/0284186X.2015.1007212","article-title":"A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma","volume":"54","author":"Rueda","year":"2015","journal-title":"Acta Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.987_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106745","article-title":"Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival","volume":"9","author":"Tarella","year":"2014","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.jtct.2025.12.987_bib0033","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/bloodadvances.2024012760","article-title":"Defining primary refractory large B-cell lymphoma","volume":"8","author":"Bock","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.12.987_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106700","article-title":"Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma","volume":"110","author":"Ulu","year":"2021","journal-title":"Leuk Res"},{"issue":"23","key":"10.1016\/j.jtct.2025.12.987_bib0035","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.987_bib0036","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.12.987_bib0037","article-title":"Oncogenic mutations and tumor microenvironment alterations of older patients with diffuse large b-cell lymphoma","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.987_bib0038","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00277-021-04470-7","article-title":"Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma","volume":"00","author":"Mozas","year":"2021","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.987_bib0039","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1007\/s00277-021-04650-5","article-title":"The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis","volume":"100","author":"Wullenkord","year":"2021","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.987_bib0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A review of autologous stem cell transplantation in lymphoma","volume":"12","author":"Zahid","year":"2017","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672502648X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672502648X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:32:59Z","timestamp":1778355179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672502648X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S266663672502648X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.987","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding Hodgkin and B-Cell Non-Hodgkin Lymphoma Progression in Patients Awaiting Autologous Transplant in a Resource-Constrained Setting","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}